TITLE

Lymphoseek data hit the literature

PUB. DATE
March 2013
SOURCE
Medical Device Daily;3/27/2013, Vol. 17 Issue 59, Special section p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This article reports that the data behind the trials of Navidea Biopharmaceuticals' new cancer tracer drug Lymphoseek will appear on the online edition of the "Annals of Surgical Oncology."
ACCESSION #
86441658

 

Related Articles

  • New diagnostic agent approved for lymphatic mapping. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;4/15/2013, Vol. 70 Issue 8, p648 

    The article announces the U.S. Food and Drug Administration approval of technetium Tc 99m tilmanocept injection of Lymphoseek from Navidea Biopharmaceuticals Inc. as an aid in identifying the first lymph node that drains the primary tumor site in patients with breast cancer or melanoma. The FDA...

  • Amyloid Imaging. Orenstein, Beth W. // Radiology Today;Apr2013, Vol. 14 Issue 4, p12 

    The article discusses the guidelines for Amyvid positron emission tomography (PET) use issued by Society of Nuclear Medicine and Molecular Imaging (SNMMI) and Alzheimer's Association. In April 2012, the Food and Drug Administration (FDA) approved florbetapir, a tracer (trade name Amyvid), for...

  • FDA Dings Imaging Agent for Lack of Training Program. Shaffer, Catherine // BioWorld Today;3/21/2011, Vol. 22 Issue 54, p1 

    This article reports on the complete response letter issued by the U.S. Food and Drug Administration (FDA) to Eli Lilly and Co. and its subsidiary Avid Radiopharmaceuticals Inc. for its new drug application for Amyvid, an imaging agent to detect beta amyloid plaque in the brain. A reader...

  • Product Briefs.  // Cardiovascular Devices & Drugs;Feb2009, Vol. 15 Issue 2, p23 

    The article reports on the submission of a new drug application to the U.S. Food and Drug Administration (FDA) by King Pharmaceuticals for its CorVue injection. The product is a cardiac pharmacologic stress single-photon-emission computed tomographic (SPECT) imaging agent aimed at patients with...

  • New Drugs of 2013, Part 1. CHANG, JENNIFER T.; CHUA, JOSHUA R.; DAY, JENNIFER M.; HONG, SEPTIMA B.; IWAMIYA, NATALIE; JUNG, STEPHEN; KARIM, FATIMA A.; LEE, ANTHONY; MAEDA, CHRISTINA Y.; MONROE, C. DOUGLAS; MOO, CHRISTOPHER; PATEL, HITEN L.; PETERSON, CONNIE W.; POWERS, DANIEL C.; RICHMOND, CATHLENE; TRAN-PUGH, ANNE N. // California Journal of Health-System Pharmacy;Mar/Apr2014, Vol. 26 Issue 2, p31 

    No abstract available.

  • Tilmanocept May Improve Sentinel Node Detection.  // Radiology Today;May2013, Vol. 14 Issue 5, p40 

    The article discusses U.S. Food and Drug Administration (FDA) approved technetium, also known as tilmanocept has been identified cancerous lymph nodes, as per the clinical trial for the dye. It states that cancer diagnosis surgeons can easily determine whether cancer is spread to sentinel nodes...

  • FDA adds warning to gadolinium-based contrast agents.  // Cardiology Today;Nov2010, Vol. 13 Issue 11, p40 

    This article reports on the new policy issued by the U.S. Food and Drug Administration that requires adding label warnings to gadolinium-based contrast agents about the risk for a rare fatal condition.

  • CONTRASTING STORIES. Valenza, Tor // Imaging Economics;Dec2007, Vol. 20 Issue 12, p36 

    The article reports on various developments related to contrast agents in the U.S. It is stated that veteran gadolinium-based compound and micro-bubble contrast agents are getting new black box warning from the Food and Drug Administration (FDA). Meanwhile, radiologists are looking again to the...

  • FDA seeks warnings for contrast agents.  // Medical Device Daily;9/13/2010, Vol. 14 Issue 177, p8 

    This article focuses on the plan of the U.S. Food and Drug Administration (FDA) to require makers of gadolinium-based contrast agents to apply a warning to product labels stating that its usage is inappropriate for patients with acute kidney injury or severe chronic kidney disease.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics